We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Azura Ophthalmics announced positive topline results ...
—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— TEL AVIV, Israel--(BUSINESS ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AZR-MD-001 0.5% for the treatment of meibomian gland ...
TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...
—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— "We are very encouraged by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results